Treatment Selection in Advanced Prostate and Bladder Cancer: Navigating an Evolving Therapeutic Landscape

Treatment Selection in Advanced Prostate and Bladder Cancer: Navigating an Evolving Therapeutic Landscape

Introduction:

The field of oncology is constantly evolving, with new treatment options and strategies emerging at a rapid pace. In this article, we will explore two studies that shed light on treatment selection in advanced prostate and bladder cancer, and discuss the implications for clinical practice. Specifically, we will delve into the considerations surrounding the use of androgen receptor (AR) targeted therapies versus chemotherapy in metastatic hormone-sensitive prostate cancer (mHSPC), as well as the role of neoadjuvant chemotherapy in locally advanced bladder cancer.

Treatment Selection in mHSPC:

The ASCO GU 2020 study titled "Treatment Selection in mHSPC: Considerations Now and Downstream in an Evolving Therapeutic Landscape" provides valuable insights into the optimal treatment approach for mHSPC. The study compared the use of androgen deprivation therapy (ADT) plus apalutamide versus ADT plus placebo in men who had received either hormone therapy or taxane chemotherapy as their next treatment.

The results of the study demonstrated that ADT plus apalutamide (a novel AR targeted therapy) was favored over ADT plus placebo, with a significant improvement in progression-free survival 2 (PFS2). This indicates that incorporating apalutamide into the treatment regimen can delay disease progression in this patient population. However, the study raises an important question - should we consider molecular status when choosing between chemotherapy and AR targeted therapies?

Further analysis revealed that docetaxel, a chemotherapy agent, did not confer an overall survival (OS) benefit in patients with the Basal subtype of mHSPC. In contrast, patients with the Luminal B subtype experienced a significant OS benefit when docetaxel was added to ADT. Interestingly, patients with the Basal subtype had better OS when treated with ADT alone compared to those with the Luminal B subtype.

This suggests that molecular subtyping could play a crucial role in treatment selection for mHSPC. Identifying the molecular subtype of the tumor may help guide clinicians in deciding whether to opt for AR targeted therapies or chemotherapy. By tailoring treatment to the individual patient's molecular profile, we can potentially optimize outcomes and improve patient survival.

Neoadjuvant Chemotherapy in Locally Advanced Bladder Cancer:

In the NEJM study titled "Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer," researchers investigated the role of neoadjuvant chemotherapy in improving outcomes for patients with locally advanced bladder cancer.

The study compared the use of neoadjuvant chemotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) followed by cystectomy versus cystectomy alone. The findings revealed that the group assigned to receive neoadjuvant M-VAC and cystectomy had a higher five-year survival rate compared to the group assigned to cystectomy alone (85% vs. 82%).

Furthermore, the study showed a 33% reduction in the estimated risk of death in the neoadjuvant chemotherapy group. This survival benefit was strongly associated with down-staging of the tumor to pT0, indicating that neoadjuvant chemotherapy can effectively shrink the tumor and improve long-term outcomes.

These results highlight the importance of considering neoadjuvant chemotherapy as a treatment option for locally advanced bladder cancer. By administering chemotherapy before surgery, we can potentially increase the chances of complete tumor eradication and improve overall survival.

Actionable Advice:

1. Molecular Subtyping: In the context of mHSPC, consider molecular subtyping of the tumor to guide treatment selection. Identifying the Basal or Luminal B subtype may help determine whether chemotherapy or AR targeted therapies should be prioritized.

2. Neoadjuvant Chemotherapy: For patients with locally advanced bladder cancer, discuss the option of neoadjuvant chemotherapy followed by cystectomy. This approach has shown promising results in down-staging tumors and improving overall survival.

3. Multidisciplinary Collaboration: Encourage multidisciplinary collaboration between urologists, medical oncologists, and pathologists to optimize treatment decisions. By leveraging the expertise of different specialists, we can ensure that patients receive the most appropriate and effective therapies.

Conclusion:

The evolving therapeutic landscape in advanced prostate and bladder cancer necessitates careful consideration of treatment options. The ASCO GU 2020 study emphasizes the importance of molecular subtyping in mHSPC, while the NEJM study highlights the benefits of neoadjuvant chemotherapy in locally advanced bladder cancer.

By incorporating molecular profiling and neoadjuvant chemotherapy into our treatment approaches, we can personalize therapies and improve outcomes for patients. However, it is crucial to remember that each patient is unique, and treatment decisions should be made on an individual basis, considering factors such as comorbidities, patient preferences, and treatment tolerability.

By staying abreast of the latest research and fostering multidisciplinary collaboration, we can continue to refine our treatment strategies and provide the best possible care for patients with advanced prostate and bladder cancer.